Evidence map›Paper›PMID 42261280›Full record

ArticleNeuro-oncology advances

Educational needs in neuro-oncology: Insights from the European Society for Medical Oncology Central Nervous System Faculty Survey.

Oriol Mirallas, Giulia Cerretti, Anna Sophie Berghoff, Dieta Brandsma, Filip De Vos, Julia Furtner, Norbert Galldiks, Giuseppe Lombardi, Slavka Lukacova, Evangelia Razis and 4 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Oriol MirallasMedical Oncology Department, Vall d'Hebron Hospital Campus and Vall d'Hebron Institute of Oncology (VHIO), Passeig de la Vall d'Hebron, 119-129, Barcelona 08035, Spain (O.M.).ORCID https://orcid.org/0000-0002-8492-5195
Giulia CerrettiDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy (G.C.).ORCID https://orcid.org/0000-0002-2849-0537
Anna Sophie BerghoffDivision of Oncology / Department of Medicine 1, Medical University of Vienna (A.S.B.).ORCID https://orcid.org/0000-0001-9379-6797
Dieta BrandsmaDepartment of Neurology, Netherlands Cancer Institute, Amsterdam, The Netherlands (D.B.).ORCID https://orcid.org/0000-0001-7998-9904
Filip De VosDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands (F.D.V.).ORCID https://orcid.org/0000-0002-9082-5991
Julia FurtnerResearch Center for Medical Image Analysis and Artificial Intelligence (MIAAI), Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria (J.F.).ORCID https://orcid.org/0000-0001-8258-3681
Norbert GalldiksDept. of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Inst. of Neuroscience and Medicine (INM-3), Research Center Juelich, Juelich, Germany; and Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany (N.G.).ORCID https://orcid.org/0000-0002-2485-1796
Giuseppe LombardiDepartment of Medical Oncology, Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy (G.L.).ORCID https://orcid.org/0000-0003-1316-2132
Slavka LukacovaDepartment of Oncology, Department of Clinical Medicine, Aarhus University & Aarhus University Hospital, Aarhus, Denmark (S.L.).ORCID https://orcid.org/0000-0002-2875-095X
Evangelia Razis3rd oncology department, Hygeia Hospital, Athens, Greece (E.R., E.L.R.).ORCID https://orcid.org/0000-0003-3873-2947
Ghazaleh TabatabaiDepartment of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, Eberhard Karls University Tübingen, Germany (G.T.).ORCID https://orcid.org/0000-0002-3542-8782
Emilie Le RhunDepartment of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland (E.L.R).ORCID https://orcid.org/0000-0002-9408-3278
Enrico FranceschiNervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy (E.F.).ORCID https://orcid.org/0000-0001-9332-4677
Giuseppe MinnitiDepartment of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Policlinico Umberto I, Rome, Italy.ORCID https://orcid.org/0000-0003-1239-1603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary central nervous system (CNS) tumors are rare malignancies with limited treatment options, resulting in high mortality. Unlike other solid tumors, CNS tumors present unique challenges that impact the health-related quality of life (HRQoL) of patients and caregivers. Effective management requires balancing oncologic treatment with the control of neurocognitive deficits, epilepsy, and other neurological symptoms. Methods: The European Society for Medical Oncology (ESMO) CNS Faculty conducted a consensus process to identify the most pressing educational priorities for physicians managing CNS malignancies. This process involved structured data collection and expert input to determine critical areas for disease-specific education and training. Results: The consensus process highlighted key educational gaps in managing CNS tumors, emphasizing the need for a multidisciplinary approach to optimize therapeutic strategies, improve survival outcomes, enhance HRQoL during treatment and survivorship, and facilitate access to emerging therapies. Physicians reported that comprehensive, disease-specific education is essential to address these challenges effectively. Conclusion: CNS tumors require targeted educational initiatives to equip healthcare providers with the knowledge and skills necessary for optimal patient care. The ESMO CNS Faculty consensus underscores the importance of structured, disease-specific training to improve outcomes, support HRQoL, and advance oncology education in the management of CNS malignancies.

Indexed as

clinical research trainingCNS tumorsmolecular diagnosticsneuro-oncology educationsupportive care

Identifiers

PMID42261280
PMCPMC13242925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.